Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of alemtuzumab (Campath-1H) monoclonal antibody in patients with relapsed and resistant classical Hodgkin's disease.

Next Previous
X
Search
Trial Profile

Study of alemtuzumab (Campath-1H) monoclonal antibody in patients with relapsed and resistant classical Hodgkin's disease.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Nov 2018 Planned End Date changed from 1 Sep 2006 to 5 Sep 2006.
    • 30 Jun 2009 Primary endpoint identified as response rate as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top